Skip to Content Skip to Search

Results announcement for the second quarter 2014

GSK delivers Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis (both CER). Q2 dividend 19p (+6%).

Issued: London UK

GSK delivers Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis (both CER). Q2 dividend 19p (+6%).

View full Q2 2014 results (PDF)

  • Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis and CER
  • Q2 dividend 19p (+6%)
  • Significant strategic progress made with 3-part Novartis transaction on track for completion in H1 2015
  • Transition of respiratory portfolio underway
  • Further significant pipeline launches, approvals and filings
  • Pipeline opportunity remains substantial with over 40 NMEs in late stage development